PTC299
Phase 2Small molecule
PTC299 is one of 118 small molecule programs targeting Neurofibromatosis. It is currently in Phase 2.
4
Indications
5
Total Trials
0
Active Trials
117
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adriamycin
GGynecologic Oncology Group
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
PTC299
PPTC Therapeutics
Phase 2
Megace
Bristol-Myers SquibbPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Spravato
WWim Janssens
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-191 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PTC299. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- PPTC Therapeutics